Medical Developments International Limited Stock

Equities

MVP

AU000000MVP2

Pharmaceuticals

Market Closed - Australian S.E. 02:10:45 2024-04-19 am EDT 5-day change 1st Jan Change
0.565 AUD +3.67% Intraday chart for Medical Developments International Limited -3.42% -25.66%
Sales 2024 * 34.5M 22.14M Sales 2025 * 41.1M 26.37M Capitalization 47.04M 30.18M
Net income 2024 * -14M -8.98M Net income 2025 * -6M -3.85M EV / Sales 2024 * 0.96 x
Net cash position 2024 * 13.9M 8.92M Net cash position 2025 * 8M 5.13M EV / Sales 2025 * 0.95 x
P/E ratio 2024 *
-3.34 x
P/E ratio 2025 *
-7.36 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.25%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Medical Developments International Limited, H1 2024 Earnings Call, Feb 29, 2024
Medical Developments International Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Medical Developments International Limited(ASX:MVP) dropped from S&P/ASX Emerging Companies Index CI
Transcript : Medical Developments International Limited, 2023 Earnings Call, Aug 31, 2023
Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023 CI
Medical Developments International Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Medical Developments International Limited Announces Resignation of David Williams from Board CI
Medical Developments International Searches for Partner to Commercialize Pain Relief Product in the US MT
Medical Developments International Limited(ASX:MVP) dropped from S&P/ASX All Ordinaries Index CI
Transcript : Medical Developments International Limited, H1 2023 Earnings Call, Feb 24, 2023
Medical Developments International Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Medical Developments Stops Clinical Trial Preparation for Penthrox in China; Shares Rise 6% MT
Medical Developments International Limited Discontinues China Clinical Trials CI
Medical Developments International Limited Provides Revenue Guidance for the Year 2023 CI
Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022 CI
More news

Latest transcript on Medical Developments International Limited

1 day+3.67%
1 week-3.42%
Current month-5.83%
1 month-8.13%
3 months-41.75%
6 months-34.30%
Current year-25.66%
More quotes
1 week
0.54
Extreme 0.54
0.59
1 month
0.54
Extreme 0.54
0.64
Current year
0.54
Extreme 0.54
1.08
1 year
0.54
Extreme 0.54
1.80
3 years
0.54
Extreme 0.54
6.25
5 years
0.54
Extreme 0.54
11.78
10 years
0.54
Extreme 0.54
11.78
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 20-10-31
Director of Finance/CFO - 22-05-15
Chief Operating Officer - -
Members of the board TitleAgeSince
Chairman 61 20-10-13
Director/Board Member - 23-08-31
Director/Board Member - 13-09-26
More insiders
Date Price Change Volume
24-04-19 0.565 +3.67% 34 927
24-04-18 0.545 -0.91% 52,219
24-04-17 0.55 0.00% 53,936
24-04-16 0.55 -4.35% 167,231
24-04-15 0.575 -1.71% 48,661

Delayed Quote Australian S.E., April 19, 2024 at 02:10 am EDT

More quotes
Medical Developments International Limited is an Australia-based company that delivers emergency medical solutions dedicated to improving patient outcomes in both domestic and international markets. The Company operates in two segments: Pain Management and Respiratory. The Pain Management segment is engaged in the supply of analgesia for acute and procedural pain. The Company manufactures inhaled analgesic, Penthrox (the Green Whistle), at manufacturing facilities at Scoresby and Springvale in Victoria, Australia. Penthrox is sold into domestic and international markets through distribution partnerships and direct in-market capability. The Respiratory segment is a supplier of respiratory products including asthma and chronic obstructive pulmonary disease (COPD) space chambers, peak flow meters, portable nebulizers and silicone face masks. Respiratory supplies into Australia, the United States of America, Europe, and Asia through partnerships with distributors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings